Vertex Pharmaceuticals Inc. and two academic investigators contend that a missed primary endpoint, a data snafu and atypical results in placebo patients all should take a back seat to FEV1 improvements produced by the company's VX-809 plus Kalydeco ivacaftor in a Phase II cystic fibrosis trial.

A clearer picture of the study should emerge shortly, as final data from all patients are expected by mid-year.